Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 FY- Text added to 2021 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
AAV, acid, Actemra, Alexion, ALI, arachidonic, AUD, Avigen, BARDA, biobehavioral, Biohaven, Biomedical, Biopharma, cancel, cardiopulmonary, cellular, chlorine, Clene, concept, contemplated, countermeasure, cycle, Denovo, Division, etesevimab, fenebrutinib, fewest, fifteen, gas, Genzyme, GlaxoSmithKline, GmbH, hepatocellular, ill, Kazia, kg, Kintara, Laminar, Leasehold, lethality, MCM, mild, molnupiravir, murine, neural, nirmatrelvir, ovine, PAXLOVID, permeability, ponesimod, Ponvory, poster, prepayment, Psychiatry, reclassified, ReDIRECT, refunded, Repurposing, revert, Ridgeback, ritonavir, scan, Secretary, sheep, sotrovimab, spend, sublicensing, substantive, tocilizumab, tolebrutinib, tract, twelve, vector, week, weighing
Valuein 2020 FY filing- Value in 2021 FY filing
Original filings
Filing view